Trisalus Life Sciences, INC 10-Q quarterly reports

TriSalus Life Sciences reports a net income of $1.539 million for Q1 2026, a significant turnaround from a net loss of $10.375 million in Q1 2025, driven by gains in fair value of financial instruments.

TriSalus Life Sciences, Inc. announced a 50.9% revenue increase for the nine months ended September 30, 2025, despite a significantly widened net loss primarily due to non-cash charges from preferred stock conversion.

TriSalus Life Sciences, Inc. reported significant revenue growth in Q2 2025, driven by new product launches, but continues to face substantial net losses and going concern uncertainties.

TriSalus Life Sciences saw a 42% increase in revenue in Q1 2025, driven by increased sales of its TriNav infusion system, but continues to operate at a loss.

TriSalus Life Sciences reports a 41.5% increase in revenue for the third quarter of 2024 compared to the same period in 2023, driven by increased sales of its TriNav infusion system.

TriSalus Life Sciences, Inc. reported a significant 59.7% increase in revenue for the second quarter of 2024, primarily attributed to strong sales of its TriNav Infusion System, despite facing challenges in its clinical development programs.

TriSalus Life Sciences saw a significant revenue increase of 116% in the first quarter of 2024, driven by higher sales of its TriNav infusion system.